Reference

Substance Context Library

A therapist-facing reference card per substance class: what to know when a patient is using alcohol, opioids, cannabis, stimulants, or benzodiazepines. Recognition, role, and routing, not scoring.

Plain-language clinical reference, not a scored screener and not a diagnostic tool. For brief validated screening, use the named instrument per substance and obtain it from its licensed source. When in doubt about safety, escalate.

Alcohol

The most prevalent substance use disorder in U.S. adults; withdrawal in heavy daily drinkers can kill. Hepatic, neurologic, and cardiac complications are commonly missed by clinicians who default to "they drink, but it's social."

A. In-session observable signs

Physical, behavioral, narrative — what you actually see.

Smell of alcohol on breath; glassy eyes; slurred speech; unsteady gait at intake.
Tremor (fine, postural), diaphoresis, anxiety, or mild tachycardia in a daily drinker who hasn't had a drink today — early withdrawal.
Frequent cancellations clustered on Monday mornings; arriving late from "traffic" repeatedly.
Escalating self-reports of "I just had a few" that don't match the partner's account or the missed-work pattern.
Memory gaps the patient cannot account for ("I don't remember how I got home").
Stigmata of chronic heavy use: spider angiomata, palmar erythema, jaundice or scleral icterus, easy bruising, ascites.

B. When use crosses into clinical concern

Original pattern groupings (not the AUDIT items, not the DSM-5 criterion list).

Pattern crosses a sustainability line

Daily drinking, especially exceeding NIAAA low-risk limits (≤1/day for women, ≤2/day for men) sustained over months.
Drinking to function — morning, before tasks, before parenting hours.
Drinking alone in escalating quantities; drinking through illness.
Heavy episodic drinking (4+ / 5+ drinks per occasion for women/men) with injury, blackout, or assault.

Body has adapted

Real withdrawal on cessation: tremor, sweats, anxiety, insomnia within 6–24 hours of the last drink.
Tolerance escalation — the patient describes needing more to feel the same.
Morning "eye-opener" to "calm the shakes."

Life has narrowed around it

Cancelled commitments to drink or recover.
Partner, family, or roommate conflict centered specifically on drinking.
Hidden or lost bottles; drinking that the patient downplays or denies.
Failed planned breaks (Dry January cut short on day 3).

Harms continue without changing the behavior

DUI, ED visit, fall, work loss, relationship damage — known and attributed by the patient — and not enough to interrupt the pattern.

What is NOT in itself a clinical concern

Adult moderate social drinking within NIAAA low-risk limits, without functional impact.
Occasional binge that the patient recognizes as outside their pattern.
Religious or cultural ritual use without functional impact.

C. Medical risks to keep in view

Alcohol withdrawal can kill.

Severe withdrawal — withdrawal seizures and delirium tremens — occurs in a minority of dependent drinkers stopping abruptly, and it can be fatal without timely medical treatment. Modern treated mortality is much lower than historical untreated estimates, but the risk is still serious. Onset is typically 6–24 hours after the last drink; the seizure window is highest 24–48 hours; DTs window is roughly 48–96 hours. Abrupt cessation in a heavy daily drinker is a medical question, not a willpower question. Do not advise a heavy daily drinker to quit cold turkey at home — coordinate with a medical setting.

Hepatic. Fatty liver → alcoholic hepatitis → cirrhosis. New jaundice, ascites, or altered mental status in a heavy drinker is a same-day medical concern (hepatic encephalopathy).
Neurologic — Wernicke encephalopathy. Confusion + ophthalmoplegia + ataxia from thiamine deficiency. Often incomplete triad. Reversible if treated; if missed, progresses to Korsakoff. Any chronic heavy drinker with new confusion or gait disturbance gets thiamine before glucose, in any setting.
Cardiac. "Holiday heart" — new atrial fibrillation after a binge. Alcoholic cardiomyopathy in chronic heavy users.
Pancreatic. Acute and chronic pancreatitis; severe upper-abdominal pain in a heavy drinker is an ED visit.
Cancer. Dose-dependent risk for upper aerodigestive, breast, colorectal, and hepatocellular cancers. Worth a one-line conversation, not a moral lecture.
Pregnancy. No safe threshold has been established; fetal alcohol spectrum disorders are 100% preventable with abstinence.
Drug interactions. Additive sedation/respiratory depression with benzodiazepines and opioids. Acetaminophen hepatotoxicity at lower doses than in non-drinkers. Disulfiram-like reaction with metronidazole or disulfiram.

D. When to coordinate with a prescriber or higher level of care

A heavy daily drinker who wants to stop — medical detox conversation, not a Dry January.
New jaundice, ascites, GI bleeding, or confusion in a heavy drinker — same-day medical evaluation.
New atrial fibrillation, palpitations with syncope, or chest pain in a binge or post-binge state — ED.
Pregnancy with any alcohol use — coordinate with OB; share the "no known safe threshold" framing.
Patient interested in pharmacotherapy for AUD (naltrexone, acamprosate, disulfiram) — refer to a prescriber willing to treat AUD; this is evidence-based and underused.

E. Pitfalls non-specialists routinely miss

Assuming "they're not having shakes, so withdrawal isn't a concern" — a daily drinker who hasn't tried to stop won't show withdrawal in your office.
Missing Wernicke signs in a chronic drinker with new confusion or gait disturbance — confusion in this population is thiamine until proven otherwise.
Underweighting the seizure window in a patient who says they're "going to taper at home this weekend."
Treating "moderate" drinking by patient report as a sufficient baseline — patients systematically underreport. The partner's report is often the truer number.
Missing that AUD pharmacotherapy exists and works. Many therapists never mention naltrexone or acamprosate to AUD patients because they don't think of themselves as the person who would.
Reading occasional patient lapses as "not really an alcohol problem" when the pattern of escalation and consequence-attribution is the actual signal.

F. Documentation language (adapt, don't copy)

"Patient reports daily alcohol use of [quantity] for [duration]; describes [morning use / drinking to manage tremor / failed planned break / partner conflict centered on drinking]. Discussed that abrupt cessation in this pattern is a medical question and recommended coordination with [PCP / addiction medicine] before any attempt to stop."

"Alcohol use is interfering with [specific role obligation]; patient and clinician identified the pattern and discussed [next step — brief validated screen using AUDIT / referral to addiction medicine / consideration of AUD pharmacotherapy with prescriber]."

"New [confusion / gait disturbance / jaundice] noted this session in a patient with chronic heavy alcohol use; referred for same-day medical evaluation; thiamine and Wernicke evaluation discussed."

Sample phrasing, not a template. Replace bracketed items with your observations.

G. Sources and validated-instrument handoff

For brief validated screening: AUDIT (10-item) or AUDIT-C (3-item) — Babor et al., WHO; Bush et al. 1998. Obtain from the WHO/published source.

For diagnosis: DSM-5 alcohol use disorder criteria — APA, 2013.

Routing: For level of care, follow your facility's framework (typically ASAM-based).

Primary sources: Grant JAMA Psychiatry 2015 (NESARC-III); Schuckit NEJM 2014 (DTs); Mayo-Smith JAMA 1997 (ASAM withdrawal consensus); Sechi & Serra Lancet Neurol 2007 (Wernicke); Ettinger Am Heart J 1978 (holiday heart); NIAAA Rethinking Drinking 2023 (public-domain federal guidance); ACOG Committee Opinion 496 (FASD); IARC Monographs (cancer risk); SAMHSA TIP 45 (public domain).

This library is general clinical education to help non-addiction-specialist therapists recognize, document, and route substance use across five common classes. It does not score severity, does not produce a diagnosis, and does not replace the validated instruments. For brief validated screening, use the named instruments per substance section and obtain them from their licensed source. For diagnosis, use DSM-5 criteria. For level-of-care decisions, follow your facility's framework. For acute medical concerns — alcohol withdrawal with seizures or DTs, opioid overdose, stimulant chest pain or hyperthermia, suspected benzodiazepine withdrawal seizures, suspected serotonin syndrome — use EMS or the ED for acute medical concerns. This is general information, not medical or legal advice; follow your own clinical judgment and licensing-board guidance.

Opioids

The central risk is overdose, not withdrawal. Overdose risk concentrates at tolerance-loss windows. Medication for opioid use disorder is the evidence-based treatment that reduces mortality — and reading a patient on MOUD as "still using" is the most damaging clinical error in this domain.

A. In-session observable signs

Distinguish intoxication signs from withdrawal signs.

Acute intoxication / current use

Pinpoint pupils, nodding, slurred speech, sedation at intake.
Constipation as a chronic complaint.
Recent unintentional overdose: "I came to with my friend slapping me," reports of being given naloxone.

Withdrawal

Dilated pupils, yawning, sniffles, tearing, gooseflesh, restlessness.
Anxiety, irritability, GI complaints, muscle aches; the patient describes it as "the worst flu I've ever had."

Behavioral / narrative

New "lost prescription" or "pharmacy mistake" pattern; running out of a 30-day prescription on day 18; multiple prescribers.
Frequent ED visits for pain; injuries with vague mechanism.
Recent loss of a use partner to overdose — a major relapse risk window worth naming directly.

B. When use crosses into clinical concern

The fentanyl-contaminated supply has moved the threshold lower than for other classes.

Any non-medical use of an illicit opioid. There is no longer a casual recreational opioid use category for a non-tolerant adult — the supply is too contaminated.
Use of a prescription opioid outside the prescribed dose, route, or person.
Any acute overdose event. A naloxone reversal is a sentinel event and changes the risk level.
Use during high-risk windows: post-detox, post-jail, post-residential, after a self-imposed break. Tolerance has dropped; the same dose can kill.
Concurrent CNS depressant use — benzodiazepines, alcohol, gabapentinoids — in any opioid user.
Pregnancy with any opioid exposure — immediate prescriber / OB coordination, regardless of source.

What is NOT in itself a clinical concern

Stable, monitored prescription opioid use for a chronic pain condition under a single prescriber with pharmacy-monitored fills and no functional decline. Worth a conversation, not a red flag.
Stable maintenance on buprenorphine or methadone (MOUD). This is the evidence-based treatment for opioid use disorder. It substantially reduces overdose mortality. A patient on stable MOUD is in treatment, not in active addiction. Treating MOUD as "still using" is the most damaging clinical error in this domain.

C. Medical risks to keep in view

Overdose is the central risk. Naloxone reverses it.

Opioids depress respiratory drive; death is hypoxic. Intranasal naloxone has been over-the-counter in the U.S. since 2023. For any patient who uses opioids, lives with someone who does, or uses any illicit substance, normalize naloxone access in the home.

Tolerance-loss overdose windows. Post-detox, post-incarceration, post-residential, and after any self-imposed abstinence break carry steeply elevated overdose mortality. Naming these windows with the patient — and ensuring naloxone is in the home — is among the highest-leverage things a therapist does.
Drug interactions that kill. Opioids + benzodiazepines: FDA Boxed Warning (2016). Opioids + alcohol: additive respiratory depression. Opioids + gabapentinoids (gabapentin, pregabalin): elevated overdose risk. Opioids + serotonergic agents (tramadol especially): rare serotonin syndrome.
Withdrawal is not the main adult overdose risk — but pregnancy changes the conversation. Adult opioid withdrawal is severely uncomfortable but not usually directly lethal except through complications such as dehydration. The danger is that it drives relapse to a now-tolerance-reduced supply. In pregnancy, do not advise abrupt or unsupervised stopping; coordinate with OB/addiction prescriber because medication treatment such as buprenorphine or methadone is guideline-supported and reduces relapse-related risk.
Neonatal abstinence syndrome (NAS). Babies born to mothers on opioids — prescribed, illicit, or MOUD — may need monitoring and treatment. NAS is medically managed and is not a reason to stop MOUD in pregnancy.
Cardiac and infectious. Injection use → endocarditis, abscess, cellulitis, HIV, HCV. New fever in a person who injects = endocarditis until proven otherwise. Methadone QT prolongation at higher doses.

D. When to coordinate with a prescriber or higher level of care

Any sentinel overdose event — same-day prescriber call; consider IOP/residential conversation.
Any concurrent CNS depressant prescribing (benzo + opioid) in an unaware patient — same-day prescriber call.
Any pregnancy with opioid exposure — immediate prescriber + OB coordination; do not advise stopping.
Patient interested in starting MOUD — refer to a buprenorphine prescriber (no DEA X-waiver required since 2023); methadone via licensed OTP. This is evidence-based and underused.
New fever in any person who injects — ED.
A high-risk window approaching or recent (jail release, residential discharge) — proactive contact, naloxone in the home, return-to-use plan with the patient.

E. Pitfalls non-specialists routinely miss

Reading MOUD as "still using." Buprenorphine and methadone are the medications that keep opioid-dependent people alive. A patient on stable MOUD is in treatment. The MOUD-as-failure framing is the highest-impact, most damaging error a non-addiction clinician can make.
Missing the overdose-after-tolerance-loss window — a patient returning from residential or jail is at peak risk; the same dose they used to use can now kill them.
Assuming a patient who "doesn't use opioids" isn't at fentanyl-overdose risk — counterfeit pills (pressed "Adderall," "Xanax") and stimulant-supply contamination kill people who never knowingly bought opioids.
Counseling a pregnant patient on opioids to "just stop" — untreated withdrawal in pregnancy endangers the fetus; MOUD is continued.
Treating naloxone as a "harm reduction" extra rather than the standard for the household. Over-the-counter intranasal naloxone removed the prescription barrier in 2023.
Skipping the after-overdose conversation. A naloxone reversal is a sentinel event; addressing it directly is the work, not a softer subject for "when the patient is ready."

F. Documentation language (adapt, don't copy)

"Patient reports [pattern of opioid use, source if known]. Discussed overdose risk, the fentanyl-contaminated supply, and access to over-the-counter intranasal naloxone for the home; patient agreed to obtain / already has naloxone available."

"Patient recently completed [detox / residential / jail-release]; identified as a tolerance-loss overdose-risk window. Discussed risk directly; naloxone confirmed available; return-to-use plan reviewed."

"Patient is on stable buprenorphine/methadone maintenance with [prescriber]; describes [functional improvement]; coordination via signed release with prescriber maintained."

"Patient on opioid analgesic from [prescriber] is also being prescribed [benzodiazepine] from [prescriber]; FDA Boxed Warning combination noted; coordination with both prescribers initiated with consent."

Sample phrasing, not a template. Replace bracketed items with your observations.

G. Sources and validated-instrument handoff

For brief validated screening: DAST-10 (Skinner 1982) for problematic drug use generally; TAPS or NIDA Quick Screen as alternatives. Obtain from licensed/published source.

For diagnosis: DSM-5 opioid use disorder criteria — APA, 2013.

Routing: For acute concerns: EMS / ED. For naloxone access: over-the-counter in U.S. pharmacies since 2023 (FDA Narcan OTC approval).

Primary sources: SAMHSA TIP 63 (Medications for OUD, public domain, updated 2021); Sordo BMJ 2017 (MOUD mortality reduction); Strang BMJ 2003 and Binswanger NEJM 2007 (tolerance-loss windows); Spencer NCHS Data Brief 2023 (overdose surveillance); Kariisa MMWR 2019/2022/2023 (stimulant-supply fentanyl contamination); Sun BMJ 2017 and FDA Drug Safety Communication 2016 (benzo+opioid Boxed Warning); Gomes PLoS Med 2017 (gabapentinoid+opioid); ACOG Committee Opinion 711 and Patrick JAMA 2012 (pregnancy and NAS); Wurcel OFID 2016 (endocarditis in PWID); FDA naloxone OTC approval, March 2023.

Cannabis

"It's just weed" is a 1995 statement. THC potency has risen 4× in flower and concentrates reach 60–90%. Daily concentrate use, real withdrawal, cannabinoid hyperemesis, and dose-related psychosis are the patterns therapists routinely miss because the legal status raises the bar for naming concern.

A. In-session observable signs

Conjunctival injection ("red eyes"), dry mouth, mild tachycardia, slowed reaction time, distinctive odor on clothing.
Time-sense distortion in narrative; mild paranoia or anxiety the patient may or may not attribute to recent use.
Cognitive complaints — word-finding, working memory — particularly in daily users.
Withdrawal in a daily user 1–3 days off: irritability, sleep disturbance with vivid dreams, anxiety, decreased appetite, GI upset.
Narrative shifts: from flower to concentrates (vape pens, dabs, wax); rising self-noted tolerance; failed planned breaks.

B. When use crosses into clinical concern

Four-domain grouping (original synthesis, not DSM-5 CUD criteria, not CUDIT-R items).

Exposure pattern

Daily or near-daily use; morning use; use to function (before driving, work, parenting).
Use of concentrates (vape, wax, dabs, shatter at 60–90% THC) rather than or in addition to flower.
Rising tolerance the patient notices themselves; inability to take a planned break.

Behavioral / functional

Spending more time or money than intended; failed attempts to cut down.
Missing or impaired in role obligations (work, parenting, school, treatment).
Conflict with partner, family, or roommates centered specifically on cannabis.
Use in physically hazardous situations (driving, operating equipment, childcare).

Physiological

Real withdrawal on cessation attempts (onset 1–3 days, peak day 2–6, resolves over 1–3 weeks; sleep disturbance and vivid dreams can persist 4+ weeks).
Tolerance escalation requiring concentrates to feel what flower used to do.
Cannabinoid hyperemesis syndrome (CHS): cyclic vomiting in chronic heavy users with hot-shower relief, full resolution only with cessation. Patients often have repeated ED visits without the cannabis cause being named.

Psychiatric red flags (escalation regardless of other signals)

New or worsening paranoia, perceptual disturbance, or thought-form changes in a daily high-potency user — especially adolescent or young-adult onset.
Cannabis-precipitated panic attacks that continue despite the patient's own awareness of the trigger.
Use in pregnancy or while breastfeeding — clear conversation; ACOG 722.
Adolescent onset still using daily into adulthood — different risk profile than adult-onset.
Co-occurring serious mental illness (psychotic-spectrum, bipolar I) where ongoing cannabis use is destabilizing.

What is NOT in itself a clinical concern

Adult, infrequent recreational use without functional impact.
Medical cannabis under a state program for an indication, without escalation of dose or functional problems.
Deliberate, articulated harm-reduction substitution (e.g., choosing cannabis over alcohol) — a clinical conversation, not a flag in itself.

C. Medical risks to keep in view

Cannabis withdrawal is real. Recognized in DSM-5 since 2013; onset 1–3 days, peak day 2–6, resolves over 1–3 weeks, with sleep and vivid-dream symptoms persisting 4+ weeks. The presence of withdrawal on cessation is one of the clearest signals use has become physiologically embedded — therapists routinely miss this and tell patients "cannabis isn't addictive."
Cannabinoid hyperemesis syndrome. Increasingly common with high-potency products. Important because patients present repeatedly to the ED and are not connected to the cannabis cause; the therapist who hears the story can name it.
Psychosis dose-response. Substantial evidence linking high-potency, daily, adolescent-onset use to incident psychotic disorder. Practical signal: a daily high-potency user developing paranoia or perceptual disturbance warrants escalation regardless of premorbid history.
Pregnancy. ACOG 722 discourages use; THC crosses the placenta and enters breast milk; associations with lower birth weight. Counsel and document; not a referral emergency in itself.
Respiratory. Long-term smoking is associated with chronic bronchitis symptoms (NASEM 2017 substantial-evidence finding).
Driving. Moderate-evidence association with increased motor vehicle crash risk (NASEM 2017).

D. When to coordinate with a prescriber or higher level of care

New psychotic features in a daily high-potency user — same-day psychiatric evaluation.
Suspected CHS — coordinate with PCP/GI; cessation is curative; antiemetics are limited.
Pregnancy with use — OB conversation; share ACOG framing.
Co-occurring serious mental illness destabilizing on cannabis — psychiatric coordination.
Patient wants to stop but cannot — consider IOP referral or addiction-medicine consult; brief screen via CUDIT-R is appropriate.

E. Pitfalls non-specialists routinely miss

Telling patients "cannabis isn't addictive" — withdrawal is recognized in DSM-5 and the time course is well established.
Missing CHS in a patient with repeated ED visits for unexplained vomiting and hot-shower-seeking.
Treating concentrate (dab pen) exposure as equivalent to 1990s flower — the THC dose is 10–20× higher.
Under-recognizing the psychosis dose-response signal in adolescent and young-adult onset users.
Over-calling cannabis use in adults with infrequent recreational use — the credibility cost destroys therapeutic alliance and the card's value depends on both sides of this.
Treating "medical cannabis under a state program" as automatically benign — escalation patterns can still occur and warrant the same conversation.

F. Documentation language (adapt, don't copy)

"Patient reports daily cannabis use (concentrate, ~X uses/day), with self-reported tolerance escalation over the past Y months. Reports unsuccessful attempt to take a one-week break, citing irritability and sleep disturbance on day 2–3."

"Cannabis use is interfering with [specific role obligation]; patient and clinician identified the pattern and discussed [next step — brief validated screen via CUDIT-R / referral to addiction medicine / IOP referral for severity stratification]."

"Patient describes repeated episodes of cyclic vomiting with hot-shower relief in the context of chronic heavy cannabis use; cannabinoid hyperemesis syndrome considered; recommended PCP evaluation and cessation."

Sample phrasing, not a template. Replace bracketed items with your observations.

G. Sources and validated-instrument handoff

For brief validated screening: CUDIT-R (Adamson et al. 2010) — 8 items; obtain from the published source.

For diagnosis: DSM-5 cannabis use disorder criteria — APA, 2013.

Routing: For level of care, follow your facility's framework.

Primary sources: Volkow NEJM 2014; Hall & Degenhardt Lancet 2009; ElSohly Biol Psychiatry 2016 (potency shift); NASEM 2017 (federal consensus report); Bonnet & Preuss Subst Abuse Rehabil 2017 (withdrawal); Allen Gut 2004 and Sorensen J Med Toxicol 2017 (CHS); Di Forti Lancet Psychiatry 2019 (EU-GEI psychosis); Marconi Schizophr Bull 2016 (meta-analysis); ACOG Committee Opinion 722.

Stimulants

Cocaine, methamphetamine, prescription amphetamines outside parameters, MDMA, synthetic cathinones. Cardiac and psychotic risks are routinely under-weighted by clinicians whose addiction training centered on opioids and alcohol. Fentanyl contamination of the stimulant supply means non-opioid users die of opioid overdoses.

A. In-session observable signs

Tachycardia, mydriasis, diaphoresis, jaw clenching/bruxism, pressured speech, agitation.
Weight loss across visits; dental wear (especially methamphetamine: "meth mouth"); skin lesions from picking; nasal septal complaints (cocaine insufflation).
Missed sleep across multiple days; paranoid mentions or persecutory framing.
Post-binge "crash" presentations: profound fatigue, hypersomnia, dysphoria, anhedonia, suicidal ideation.
Reports of "stimulant" overdose, loss of consciousness, blue lips, or naloxone given — assume opioid contamination of supply.

B. When use crosses into clinical concern

Any binge associated with cardiac symptoms (chest pain, palpitations with syncope, severe headache, neurologic deficit).
New paranoia, perceptual disturbance, or persistent psychotic features — particularly in methamphetamine users.
Persistent suicidal ideation during the post-binge crash or early abstinence.
Pregnancy with any stimulant use — placental abruption, preterm labor, IUGR concerns.
Injection use of any stimulant — endocarditis risk; new fever = ED.
Counterfeit prescription pill use ("pressed Adderall," "pressed Xanax") — assume fentanyl exposure.
Sustained agitation the patient/family cannot de-escalate.

What is NOT in itself a clinical concern

Stable, prescribed amphetamine therapy for diagnosed ADHD taken as directed under a single prescriber, with no functional decline or escalation. (Concern arises with dose escalation outside the prescription, route changes, or multiple prescribers.)

C. Medical risks to keep in view

Chest pain in a stimulant user is ACS until proven otherwise.

Stimulants raise heart-rate and blood-pressure demand on the heart while simultaneously constricting coronaries. Cocaine and methamphetamine can precipitate MI, stroke, and aortic dissection in young patients with otherwise unremarkable cardiac history. The default is ED evaluation, not a clinic appointment — even when the patient looks well. This direct framing is deliberate; the harm of under-escalating is much larger than the harm of over-referring.

Cerebrovascular. Ischemic and hemorrhagic stroke in young stimulant users; severe sudden headache, unilateral weakness, facial droop, vision change → EMS.
Methamphetamine cardiomyopathy. New shortness of breath, leg edema, or exercise intolerance in a chronic methamphetamine user → cardiology evaluation.
Hyperthermia. Core temp >40°C drives rhabdomyolysis, DIC, AKI, hepatic injury, death. Classic in MDMA users at festivals/raves; can occur with cocaine, methamphetamine, synthetic cathinones. Hot, flushed, dry-skinned, exerting, used recently = emergency.
Serotonin syndrome. MDMA, methamphetamine, or cocaine plus serotonergic agent (SSRI, SNRI, MAOI, linezolid, tramadol, dextromethorphan, triptan) → altered mental status + autonomic hyperactivity + neuromuscular abnormalities (clonus, hyperreflexia).
MDMA hyponatremia. SIADH plus excessive water intake at events; fatal cerebral edema, especially in young women. Confusion, headache, or seizure in a young MDMA user who has been drinking large volumes of water → EMS.
Stimulant-induced psychosis. Dose- and chronicity-related; methamphetamine psychosis can persist days–weeks after intoxication and may unmask or accelerate a primary psychotic disorder.
Suicide during the crash. Withdrawal is primarily psychiatric — dysphoria, hypersomnia, anhedonia, craving, suicidal ideation. Not medically dangerous in itself, but the suicide signal during the post-binge crash and early abstinence is significant and routinely under-weighted.
Pregnancy. Cocaine and methamphetamine raise placental abruption, preterm labor, IUGR, and neonatal complications. Vaginal bleeding, severe abdominal pain, or decreased fetal movement in a stimulant-using pregnant patient → obstetric emergency evaluation.
Route-related. Injection → endocarditis (new fever = ED), abscess, soft-tissue infection. Insufflation (cocaine) → septal perforation, sinusitis, sinonasal destruction. Smoking methamphetamine → severe dental disease, airway/pulmonary effects.
Supply contamination. Fentanyl in the stimulant supply is a leading driver of overdose deaths in people who do not intend to use opioids. Counterfeit pressed pills carry the same risk. Naloxone for any stimulant user is reasonable.

D. When to coordinate with a prescriber or higher level of care

Any chest pain, severe headache, focal neurologic deficit, or aortic-tearing pain in a stimulant user → EMS / ED.
Hyperthermia, severe agitation with rigidity/clonus, or signs of serotonin syndrome → EMS / ED.
New or worsening psychosis, especially if persisting beyond intoxication → same-day psychiatric evaluation.
Active suicidal ideation during the post-binge crash → safety plan, same-day evaluation, 988 / local crisis resources.
Pregnancy with stimulant use → immediate OB coordination.
Injection use with new fever → ED.
Any naloxone reversal in a "stimulant" user → same as opioid overdose response; the supply is contaminated.

E. Pitfalls non-specialists routinely miss

Assuming stimulants are "less physically dangerous" than alcohol or opioids — the cardiac and cerebrovascular risk in young users is the part most often missed.
Missing the chest-pain → ACS framing in a young patient because the cardiac history is unremarkable.
Under-weighting suicide risk during the stimulant crash — withdrawal is "just" psychological, but the SI signal is the clinically important hazard.
Treating "stimulants do not have a fentanyl problem" as still true — supply contamination data have changed the overdose risk.
Missing serotonin syndrome in a patient on an SSRI who used MDMA at a festival.
Pathologizing stable prescribed amphetamine therapy for diagnosed ADHD — concern is dose escalation outside parameters, not the prescription itself.
Mistaking stimulant-induced mania for a primary bipolar episode in the moment — differentiation often requires sustained abstinence.

F. Documentation language (adapt, don't copy)

"Patient reports [pattern of stimulant use, route, frequency, last use]. Discussed cardiac and overdose risks including fentanyl contamination of the stimulant supply; patient agreed to obtain / already has naloxone in the home."

"Patient presented post-binge with significant dysphoria and passive suicidal ideation; safety plan reviewed; crisis-line resources confirmed; next-session contact scheduled within [timeframe]."

"Patient describes new persecutory beliefs in the context of daily methamphetamine use over recent weeks; referred for same-day psychiatric evaluation; coordination with [prescriber/PCP] initiated with consent."

Sample phrasing, not a template. Replace bracketed items with your observations.

G. Sources and validated-instrument handoff

For brief validated screening: DAST-10 (Skinner 1982) for problematic drug use generally; no widely-adopted brief stimulant-specific outpatient screen.

For diagnosis: DSM-5 stimulant use disorder criteria — APA, 2013.

Routing: For acute concerns: EMS / ED; for chest pain, the ED owns the validated risk tools.

Primary sources: Lange & Hillis NEJM 2001; McCord Circulation 2008 (AHA scientific statement on cocaine chest pain); Westover Arch Intern Med 2007 (stroke); Yeo Am J Med 2007 (methamphetamine cardiomyopathy); Greene 2008 and Hall & Henry Br J Anaesth 2006 (hyperthermia); Boyer & Shannon NEJM 2005 (serotonin syndrome); Rosenson Ann Emerg Med 2007 (MDMA hyponatremia); McKetin Addiction 2006 and Glasner-Edwards CNS Drugs 2014 (methamphetamine psychosis); Marshall Addiction 2011 (suicide risk); McGregor Addiction 2005 (withdrawal); Cain Obstet Gynecol 2013 (pregnancy); Wurcel OFID 2016 (endocarditis); Kariisa MMWR 2019/2022/2023 (supply contamination).

Benzodiazepines

Most patients on long-term benzodiazepines are on prescribed therapy. Physical dependence develops with sustained dosing regardless of behavior; abrupt discontinuation can cause seizures and rarely death. The therapist’s role is observation, documentation, and coordination, not pharmacology.

A. In-session observable signs

Sedation, slurred speech, memory gaps, unsteady gait, slowed reaction time.
Anxiety, panic, or sleep disruption that escalates between visits (possible interdose withdrawal with short-acting agents).
Perceptual oddities — tingling, depersonalization, sensitivity to light or sound — particularly during or after a taper attempt.
Cognitive complaints (word-finding, concentration, memory).
Narrative shifts: "lost prescription," early refill requests, multiple prescribers, running out before the month is up.

B. When use crosses into clinical concern

With benzodiazepines, the first question is often not whether this is a use disorder. It is whether the medical risk has changed.

In-session sedation that affects safety (driving, parenting after session).
Suspected combined opioid use, alcohol use, or gabapentinoid use in a chronic-benzo patient.
Evidence of escalating use beyond prescription (early refills, multiple prescribers, lost prescriptions).
Patient describes self-tapering by cutting pills, skipping doses, or stopping.
Use in a patient with new fall, fracture, or motor vehicle event.
Pregnancy with chronic benzodiazepine use (a prescriber + OB conversation, not a "just stop").

What is NOT in itself a clinical concern

Stable, monitored, long-term prescribed use under a single prescriber for an appropriate indication, with no functional decline or escalation. Physical dependence is not addiction — it is a predictable pharmacologic state that occurs in compliant patients taking exactly as prescribed.

C. Medical risks to keep in view

Do not advise the patient to skip, cut, or stop doses.

Abrupt discontinuation of chronic benzodiazepines can cause withdrawal that includes seizures and, rarely, death — a defining property of the GABAergic sedative-hypnotic class (alcohol, benzodiazepines, barbiturates). The taper is a prescriber decision, requires medical monitoring, and typically takes months rather than weeks. If the patient wants to come off, support the goal and route the conversation back to the prescriber. This is a hard medical fact, not a turf concern.

Withdrawal overlaps with the disorder being treated. Anxiety, insomnia, panic, tremor, autonomic arousal — distinguishing rebound/withdrawal from recurrence of the underlying disorder is the prescriber's call. The therapist often sees the timeline first; document and surface.
Half-life shapes time course. Short-acting agents (alprazolam, lorazepam, oxazepam) produce earlier, sharper symptoms; long-acting agents (diazepam, clonazepam) produce later, more diffuse symptoms that can persist.
Protracted symptoms. A subset of patients experience anxiety, sleep disturbance, perceptual symptoms, and cognitive complaints lasting weeks to months after discontinuation. Therapists often see patients in this window; framing it as a recognized phenomenon is clinically useful.
Benzodiazepines + opioids — FDA Boxed Warning (2016). Substantially elevated overdose mortality. If a chronic-benzodiazepine patient is also prescribed opioids, or is using them, the overdose risk has changed and the prescriber needs to know.
Benzodiazepines + alcohol. Additive CNS and respiratory depression. Worth knowing whether the patient drinks, especially evenings on top of an evening dose.
Benzodiazepines in older adults. Increased fall, fracture, and cognitive-impairment risk; AGS Beers Criteria list as potentially inappropriate.
Benzodiazepines in pregnancy. Risk/benefit is a prescriber decision; abrupt discontinuation in pregnancy carries its own risks.

D. When to coordinate with a prescriber or higher level of care

For most chronic-benzo patients, a signed release-of-information with the prescriber is a higher-yield clinical move than any session content. A two-minute prescriber call surfaces things neither party would catch alone.
Same-day call: in-session sedation affecting safety; suspected combined opioid use; evidence of escalating use beyond prescription; patient describing self-tapering by cutting pills.
Urgent call: new fall, fracture, or motor vehicle event in a chronic-benzo patient.
Routine coordination: any medication change or new clinical risk, including a new opioid, gabapentinoid, alcohol pattern, or planned pregnancy.
Patient wants to come off — support the goal, route the conversation to the prescriber, do not propose a taper schedule.

E. Pitfalls non-specialists routinely miss

Advising the patient to skip doses, cut pills, or stop — this is the highest-stakes error in this domain and is medically dangerous.
Conflating prescribed long-term use with addiction — physical dependence is not addiction.
Missing in-session sedation as a same-day prescriber call rather than a next-session topic.
Attributing escalating between-visit anxiety to "the underlying disorder" when interdose withdrawal with a short-acting agent is on the table.
Missing the benzo+opioid Boxed Warning combination when each medication is prescribed by a different clinician and neither knows.
Treating perceptual symptoms during a taper as "going crazy" rather than as recognized withdrawal phenomenology.
Amplifying online taper-protocol advice the patient brings in (e.g., from the Ashton Manual) without coordination with the prescriber.

F. Documentation language (adapt, don't copy)

"Patient on long-term prescribed [benzodiazepine] from [prescriber] for [indication]. Discussed scope of therapist role around medication; signed release-of-information for prescriber coordination obtained / on file."

"Noted [sedation / slurred speech / unsteady gait] in session today; patient confirmed no dose change; same-day call to prescriber initiated to discuss medical context."

"Patient reports escalating between-visit anxiety since [event]; pattern timeline shared with prescriber via [phone / portal] with consent; differential includes underlying-disorder recurrence vs. interdose withdrawal; prescriber to evaluate."

"Patient described attempting to self-taper by cutting pills; reviewed seizure risk associated with abrupt benzodiazepine discontinuation; supported the goal of coming off and routed the planning conversation to prescriber."

Sample phrasing, not a template. Replace bracketed items with your observations.

G. Sources and validated-instrument handoff

For brief validated screening: No standard outpatient brief screen specific to benzodiazepines; clinical interview plus prescriber coordination is the dominant approach.

For diagnosis: DSM-5 sedative, hypnotic, or anxiolytic use disorder criteria — APA, 2013.

Routing: For taper protocols: SAMHSA TIP 45 (public domain) and the Ashton Manual (Ashton 2002, copyrighted; widely circulated) are resources for the prescriber, not for the therapist to act on.

Primary sources: Lader Addiction 2011; Soyka NEJM 2017; FDA Drug Safety Communication September 2020 (Boxed Warning expansion); FDA Drug Safety Communication August 2016 (benzo+opioid Boxed Warning); Sun BMJ 2017 (concurrent benzo+opioid overdose); Rickels Arch Gen Psychiatry 1990 (discontinuation); Pétursson Addiction 1994 (withdrawal syndrome); Ashton Br J Addict 1991 (time-course concept); Higgitt BMJ 1985 (clinical management); SAMHSA TIP 45 (public domain); AGS Beers Criteria.